Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 30.04B, Biogen(BIIB) trades at $203.47. The stock has a price-to-earnings ratio of 21.37.
On 2026-07-13, Biogen(BIIB) stock traded between a low of $197.74 and a high of $203.47. Shares are currently priced at $203.47, which is +2.9% above the low and 0.0% below the high.
Biogen(BIIB) shares are trading with a volume of 567.41K, against a daily average of 1.42M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
BIIB News
As of 11:45 a.m. ET, the S&P 500 (SNPINDEX:^GSPC) fell 0.39% to 7,546.18, the Nasdaq Composite (NASDAQINDEX:^IXIC) slid 0.92% to 26,039.24 on tech weakness, and...
...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as...
Analyst ratings
61%
of 38 ratingsMore BIIB News
Wedbush raised the firm’s price target on Biogen (BIIB) to $201 from $196 and keeps a Neutral rating on the shares. The firm updated its model ahead of the Q2 e...
Jason Zemansky, an analyst from Bank of America Securities, maintained the Hold rating on Biogen. The associated price target remains the same with $217.00. Ti...
Truist upgraded Biogen (BIIB) to Buy from Hold with a $235 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking f...
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, NRG Energy Inc (Symbol: NRG) has taken over the #302 sp...
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biogen (BIIB) to $222 from $224 and keeps an Equal Weight rating on the shares. Biotech...
Analyst Jason Zemansky of Bank of America Securities reiterated a Hold rating on Biogen, boosting the price target to $217.00. Unlock powerful investing tools...
Biopharmaceuticals Analyst Pachaiyappan, along with Prof. Jeremy Shefner, M.D., Ph.D. (Barrow Neurological Institute), hold a webinar entitled, “A Quest to Outr...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.